Grand Pharmaceutical Group Limited

SEHK:512 Stok Raporu

Piyasa değeri: HK$16.0b

Grand Pharmaceutical Group Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Grand Pharmaceutical Group is forecast to grow earnings and revenue by 2.3% and 6.2% per annum respectively. EPS is expected to grow by 1.5% per annum. Return on equity is forecast to be 13% in 3 years.

Anahtar bilgiler

2.3%

Kazanç büyüme oranı

1.5%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi11.1%
Gelir büyüme oranı6.2%
Gelecekteki özkaynak getirisi13.0%
Analist kapsamı

Low

Son güncelleme22 Oct 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Grand Pharmaceutical Group Limited (HKG:512) Looks Inexpensive But Perhaps Not Attractive Enough

Sep 19
Grand Pharmaceutical Group Limited (HKG:512) Looks Inexpensive But Perhaps Not Attractive Enough

Grand Pharmaceutical Group (HKG:512) Is Paying Out A Larger Dividend Than Last Year

Jun 05
Grand Pharmaceutical Group (HKG:512) Is Paying Out A Larger Dividend Than Last Year

Market Participants Recognise Grand Pharmaceutical Group Limited's (HKG:512) Earnings

May 22
Market Participants Recognise Grand Pharmaceutical Group Limited's (HKG:512) Earnings

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Apr 25
Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Mar 25
Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

We Think Grand Pharmaceutical Group (HKG:512) Can Stay On Top Of Its Debt

Oct 20
We Think Grand Pharmaceutical Group (HKG:512) Can Stay On Top Of Its Debt

Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching

Sep 26
Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching

Grand Pharmaceutical Group's (HKG:512) Dividend Will Be Increased To HK$0.14

Jun 04
Grand Pharmaceutical Group's (HKG:512) Dividend Will Be Increased To HK$0.14

Is Grand Pharmaceutical Group (HKG:512) A Risky Investment?

May 05
Is Grand Pharmaceutical Group (HKG:512) A Risky Investment?

Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly

Nov 21
Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly

Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 43% Discount?

Sep 05
Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 43% Discount?

Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly

Aug 16
Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly

Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching

Jul 28
Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching

Grand Pharmaceutical Group's (HKG:512) Dividend Will Be HK$0.11

May 29
Grand Pharmaceutical Group's (HKG:512) Dividend Will Be HK$0.11

Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 45% Discount?

Apr 08
Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 45% Discount?

Grand Pharmaceutical Group (HKG:512) Has A Rock Solid Balance Sheet

Mar 22
Grand Pharmaceutical Group (HKG:512) Has A Rock Solid Balance Sheet

If You Like EPS Growth Then Check Out Grand Pharmaceutical Group (HKG:512) Before It's Too Late

Jan 24
If You Like EPS Growth Then Check Out Grand Pharmaceutical Group (HKG:512) Before It's Too Late

These 4 Measures Indicate That Grand Pharmaceutical Group (HKG:512) Is Using Debt Safely

Dec 13
These 4 Measures Indicate That Grand Pharmaceutical Group (HKG:512) Is Using Debt Safely

Grand Pharmaceutical Group Limited's (HKG:512) Intrinsic Value Is Potentially 45% Above Its Share Price

Nov 27
Grand Pharmaceutical Group Limited's (HKG:512) Intrinsic Value Is Potentially 45% Above Its Share Price

With EPS Growth And More, China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Is Interesting

Oct 25
With EPS Growth And More, China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Is Interesting

China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Seems To Use Debt Rather Sparingly

Sep 01
China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Seems To Use Debt Rather Sparingly

Do China Grand Pharmaceutical and Healthcare Holdings's (HKG:512) Earnings Warrant Your Attention?

Jul 12
Do China Grand Pharmaceutical and Healthcare Holdings's (HKG:512) Earnings Warrant Your Attention?

Kazanç ve Gelir Büyüme Tahminleri

SEHK:512 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (HKD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/202614,0342,5262,1352,5613
12/31/202512,8982,2121,7242,0903
12/31/202411,6452,0391,6352,1783
6/30/202410,5872,4091,4511,903N/A
3/31/202410,5582,1441,6942,164N/A
12/31/202310,5301,8801,9372,425N/A
9/30/202310,4342,1391,3492,114N/A
6/30/202310,3392,3987611,804N/A
3/31/20239,9512,2397731,823N/A
12/31/20229,5622,0797851,843N/A
9/30/20229,4031,9951,0681,829N/A
6/30/20229,2441,9101,3501,815N/A
3/31/20228,9212,1561,4101,911N/A
12/31/20218,5982,4031,4692,006N/A
9/30/20218,1312,3401,4872,001N/A
6/30/20217,6642,2771,5041,995N/A
3/31/20217,0082,0351,3511,726N/A
12/31/20206,3531,7931,1971,456N/A
9/30/20206,3061,5581,0201,400N/A
6/30/20206,2591,3238431,345N/A
3/31/20206,4251,2377901,324N/A
12/31/20196,5911,1517371,304N/A
9/30/20196,4501,0481,1771,661N/A
6/30/20196,3099441,6182,017N/A
3/31/20196,1348281,3261,713N/A
12/31/20185,9587131,0341,408N/A
9/30/20185,845642535898N/A
6/30/20185,73257036387N/A
3/31/20185,251516N/A553N/A
12/31/20174,771461N/A720N/A
9/30/20174,480413N/A708N/A
6/30/20174,190364N/A696N/A
3/31/20173,943317N/A736N/A
12/31/20163,696269N/A775N/A
9/30/20163,573241N/A807N/A
6/30/20163,450213N/A839N/A
3/31/20163,348197N/A668N/A
12/31/20153,246181N/A496N/A
9/30/20153,158187N/A439N/A
6/30/20153,071194N/A382N/A
3/31/20153,097185N/A430N/A
12/31/20143,122175N/A477N/A
9/30/20143,040150N/A602N/A
6/30/20142,958126N/A728N/A
3/31/20142,808113N/A760N/A
12/31/20132,658100N/A792N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 512's forecast earnings growth (2.3% per year) is above the savings rate (2.3%).

Kazançlar ve Piyasa: 512's earnings (2.3% per year) are forecast to grow slower than the Hong Kong market (11.5% per year).

Yüksek Büyüme Kazançları: 512's earnings are forecast to grow, but not significantly.

Gelir ve Pazar: 512's revenue (6.2% per year) is forecast to grow slower than the Hong Kong market (7.7% per year).

Yüksek Büyüme Geliri: 512's revenue (6.2% per year) is forecast to grow slower than 20% per year.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 512's Return on Equity is forecast to be low in 3 years time (13%).


Büyüyen şirketleri keşfedin